US · AMGN · DRUG MANUFACTURERS - GENERAL
Amgen Inc. (AMGN) intrinsic value and stock valuation
$435.64as of 2026-11-21 · Mkt cap 220.11B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Amgen Inc. DCF and intrinsic value
InvestorsCraft values AMGN with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from AMGN’s statements →
Amgen Inc. Graham Number
Graham Number: $72.04d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Merck & Co., Inc. (MRK) $133.72
- Novartis AG (NVS) $150.47
- Novo Nordisk A/S (NVO) $37.82
- Gilead Sciences, Inc. (GILD) $166.43
- Pfizer Inc. (PFE) $27.40
- Danaher Corporation (DHR) $220.36
- Bristol-Myers Squibb Company (BMY) $58.80
- GSK plc (GSK) $47.76
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $36.7B | $33.4B | $28.2B | $26.3B | $26B |
| Operating income | $10.7B | $7.26B | $7.9B | $9.57B | $7.64B |
| Net income | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B |
| EPSd | $14.2M | $7.56M | $12.5M | $12.1M | $10.3M |
| Operating cash flow | $9.96B | $11.5B | $8.47B | $9.72B | $9.26B |
| Capital expenditure | -$-1.86B | -$-1.1B | -$-1.11B | -$-936M | -$-880M |
| Free cash flow | $8.1B | $10.4B | $7.36B | $8.79B | $8.38B |
| Total assets | $90.6B | $91.8B | $97.2B | $65.1B | $61.2B |
| Total debt | $54.6B | $60.1B | $64.6B | $38.9B | $33.3B |
| Net debt | $45.5B | $48.1B | $53.7B | $31.3B | $25.3B |
| Total equity | $8.66B | $5.88B | $6.23B | $3.66B | $6.7B |
| Cash and short-term investments | $9.13B | $12B | $10.9B | $9.31B | $8.04B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $36.7B | $33.4B | $28.2B | $26.3B | $26B |
| Cost of revenue | $10.7B | $12.9B | $8.42B | $6.41B | $6.45B |
| Gross profit | $26B | $20.6B | $19.8B | $19.9B | $19.5B |
| Research and development expenses | $6.97B | $5.96B | $4.78B | $4.43B | $6.32B |
| Selling, general and administrative expenses | $7.05B | $7.1B | $6.18B | $5.41B | $5.37B |
| Other expenses | $1.31B | $248M | $879M | $503M | $194M |
| Operating expenses | $15.3B | $13.3B | $11.8B | $10.4B | $11.9B |
| Cost and expenses | $26.1B | $26.2B | $20.3B | $16.8B | $18.3B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $2.76B | $3.16B | $2.88B | $1.41B | $1.2B |
| Depreciation and amortization | $5.17B | $5.59B | $4.07B | $3.42B | $3.4B |
| Ebitda | $16.9B | $13.4B | $14.8B | $12.2B | $11.3B |
| Operating income | $10.7B | $7.26B | $7.9B | $9.57B | $7.64B |
| Total other income/expenses, net | -$-1.7B | -$-2.65B | -$-42M | -$-2.22B | -$-938M |
| Income before tax | $8.98B | $4.61B | $7.86B | $7.35B | $6.7B |
| Income tax expense | $1.27B | $519M | $1.14B | $794M | $808M |
| Net income | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B |
| Weighted average shares outstanding | $538M | $541M | $535M | $538M | $570M |
| Weighted average diluted shares outstanding | $542M | $541M | $538M | $541M | $573M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $9.13B | $12B | $10.9B | $9.31B | $8.04B |
| Net receivables | $9.57B | $7.5B | $7.94B | $6.39B | $5.84B |
| Inventory | $6.23B | $7B | $9.52B | $4.93B | $4.09B |
| Total current assets | $29.1B | $29B | $30.3B | $22.2B | $19.4B |
| Property, plant and equipment, net | $8.52B | $6.54B | $5.94B | $5.43B | $5.18B |
| Goodwill and intangible assets | $41B | $46.3B | $51.3B | $31.6B | $30.1B |
| Long-term investments | $6.8B | $5.36B | $4.71B | $0.00 | $0.00 |
| Total non-current assets | $61.5B | $62.8B | $66.8B | $42.9B | $41.8B |
| Total assets | $90.6B | $91.8B | $97.2B | $65.1B | $61.2B |
| Accounts payable | $2.37B | $1.91B | $1.59B | $1.57B | $1.37B |
| Short-term debt | $4.6B | $3.55B | $1.44B | $1.59B | $87M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $25.5B | $23.1B | $18.4B | $15.7B | $12.2B |
| Long-term debt | $50B | $56.5B | $63.2B | $37.4B | $33.2B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $56.4B | $62.9B | $72.5B | $45.8B | $42.3B |
| Capital lease obligations | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total liabilities | $81.9B | $86B | $90.9B | $61.5B | $54.5B |
| Common stock | $34B | $33.5B | $33.1B | $32.5B | $32.1B |
| Retained earnings | -$-25.11B | -$-27.59B | -$-26.55B | -$-28.62B | -$-24.6B |
| Accumulated other comprehensive income (loss) | -$-258M | -$-66M | -$-289M | -$-231M | -$-796M |
| Total equity | $8.66B | $5.88B | $6.23B | $3.66B | $6.7B |
| Total investments | $6.8B | $5.36B | $4.71B | $1.68B | $48M |
| Total debt | $54.6B | $60.1B | $64.6B | $38.9B | $33.3B |
| Net debt | $45.5B | $48.1B | $53.7B | $31.3B | $25.3B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B |
| Depreciation and amortization | $5.17B | $5.59B | $4.07B | $3.42B | $3.4B |
| Stock-based compensation | $494M | $530M | $431M | $401M | $341M |
| Change in working capital | -$-1.98B | $2.37B | -$-484M | -$-733M | -$-1.19B |
| Accounts receivable | -$-2.68B | $441M | -$-1.02B | -$-746M | -$-429M |
| Inventory | $886M | $2.53B | $491M | -$-742M | -$-165M |
| Accounts payable | $428M | $312M | -$-402M | $154M | -$-69M |
| Net cash provided by operating activities | $9.96B | $11.5B | $8.47B | $9.72B | $9.26B |
| Investments in property, plant and equipment | -$-1.86B | -$-1.1B | -$-1.11B | -$-936M | -$-880M |
| Acquisitions, net | -$-53M | $0.00 | -$-26.99B | -$-3.73B | -$-2.69B |
| Net cash used for investing activities | -$-1.94B | -$-1.05B | -$-26.2B | -$-6.04B | $733M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | -$-200M | $0.00 | -$-6.36B | -$-4.98B |
| Dividends paid | -$-5.12B | -$-4.83B | -$-4.56B | -$-4.2B | -$-4.01B |
| Net cash used for financing activities | -$-10.86B | -$-9.42B | $21B | -$-4.04B | -$-8.27B |
| Net change in cash | -$-2.84B | $1.03B | $3.32B | -$-360M | $1.72B |
| Cash at end of period | $9.13B | $12B | $10.9B | $7.63B | $7.99B |
| Operating cash flow | $9.96B | $11.5B | $8.47B | $9.72B | $9.26B |
| Capital expenditure | -$-1.86B | -$-1.1B | -$-1.11B | -$-936M | -$-880M |
| Free cash flow | $8.1B | $10.4B | $7.36B | $8.79B | $8.38B |
Line items
Line items
Line items
About Amgen Inc.
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
- CEO
- Robert A. Bradway
- Employees
- 31.5K
- Beta
- 0.40
Included in
Explore
Frequently asked questions
What is the intrinsic value of Amgen Inc. (AMGN)?
Amgen Inc. (AMGN) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is AMGN undervalued?
AMGN trades at a price of $435.64 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.